subject: Non - Small Cell Lung Cancer (nsclc) - Drug Pipeline Analysis And Market Forecasts To 2015 [print this page] Description Description
The industry analysis specialists new report, Non-Small Cell Lung Cancer (NSCLC) - Drug Pipeline Analysis and Market Forecasts to 2015 is an essential source of information and analysis on the global NSCLC disease market. The report identifies the key trends shaping and driving the global NSCLC disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NSCLC disease sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.
Estimates the global NSCLC disease market to be $2.8 billion in 2008. It is forecast to grow at a compound annual growth rate (CAGR) of 13.5% for the next seven years to reach $6.8 billion by 2015. This growth is primarily attributed to increased disease population and strong pipeline with more emerging therapies. The available treatment options are moderately successful in meeting the market demand. There exists a significant market potential to be tapped for any new entrant that will cater to the unmet needs. There is enormous opportunity for any drug that would offer better efficacy provided by the current players with increased safety than the current products.
Finds that that the emerging therapies in pipeline are expected to increase the competition. Emerging therapies have gained a positive perception among the physicians due to increased efficacy, safety and overall survival. The strong pipeline leads to the stiff competition in the NSCLC market and the existing market leaders need to be prepared to manage this expected dynamism in competition as there is a race to reach the blockbuster drug status.
Scope of the Report
The report analyzes market opportunities and challenges for the global NSCLC disease market. Its scope includes
Annualized global NSCLC disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
* Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
* Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes tyrosine kinase inhibitors, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK Inhibitors, glutathione S-transferase binders, growth and survival of MM cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, cyclooxygenase-2 (COX-2) inhibitors, Pan Bcl-2 inhibitors and MUC1 tumor-associated antigens etc.
* Analysis of the current and future market competition in the global NSCLC disease market. Key market players covered are F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Sanofi-aventis, Boehringer Ingelheim GmbH, and Abraxis BioScience, Inc.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
* Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NSCLC disease.
